Loading clinical trials...
Loading clinical trials...
A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension.
Conditions
Interventions
Xalacom
Cosopt
Locations
25
France
Pfizer Investigational Site
Caen, France
Pfizer Investigational Site
Clermont-Ferrand, France
Pfizer Investigational Site
Lyon, France
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Saint-Herblain, France
Pfizer Investigational Site
Darmstadt, Germany
Start Date
July 1, 2005
Completion Date
July 1, 2006
Last Updated
February 18, 2021
NCT06979752
NCT07390890
NCT05902871
NCT07218796
NCT07119580
NCT07076303
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions